Vedana Therapeutics Launches Next-Generation Migraine Prevention Antibody Targeting PACAP with $46M Series A Funding
Vedana Therapeutics, a company founded by a team of leading migraine experts, has emerged from stealth mode in Seattle after securing $46 million in Series A funding. Co-founder and CSO, Dr. Leon Garcia, is a key scientist who discovered and developed both the anti-CGRP antibody eptinezumab (now Vyepti from Lundbeck) and the anti-PACAP antibody ALD1910 (now bocunebart) at Alder BioPharmaceuticals. CEO Dr. Anurag Agarwal (formerly of Osage University Partners), CMO Dr. Ernesto Aycardi (formerly of Teva, where he led the pivotal clinical trial for Ajovy), and Executive Chair Dr. Rob Lenz (formerly of Amgen, where he led the global development of Aimovig) have also joined the company. This brings together the core team behind the three FDA-approved CGRP antibodies. Westlake BioPartners and Canaan Partners co-led the funding round, with participation from Dawn Biopharma and Alexandria Venture Investments.
The company's lead program is a long-acting, subcutaneous, self-administered anti-PACAP monoclonal antibody. PACAP (pituitary adenylate cyclase-activating polypeptide) is a neuropeptide that triggers migraines through a distinct neural pathway from CGRP, potentially offering a new option for patients who do not respond to CGRP inhibitors. Lundbeck's bocunebart (Lu AG09222), acquired through the Alder acquisition in 2019, demonstrated clinical proof-of-concept for this pathway in the Phase 2b PROCEED trial in February 2026, which met its primary endpoint of reducing monthly migraine days (MMD). Eli Lilly's LY3451838, however, failed to meet its primary endpoint in Phase 2, highlighting the challenges of designing PACAP molecules.
The second pipeline program is a bispecific antibody that simultaneously blocks both PACAP and CGRP, representing the first attempt to combine these two pathways in a single migraine treatment. Approximately 30-40% of patients do not achieve sufficient response with existing CGRP single-target antibodies such as Aimovig (erenumab, Amgen/Novartis), Ajovy (fremanezumab, Teva), Emgality (galcanezumab, Eli Lilly), and Vyepti (eptinezumab, Lundbeck), and this patient population is the direct target of the dual-target strategy. All pipeline programs are designed for subcutaneous self-administration, aiming to provide a more convenient administration method compared to Vyepti, which requires IV infusion.
The global CGRP inhibitor market is expected to reach approximately $6.5 billion in 2026 and grow to $12.5 billion by 2033, with a compound annual growth rate of 9.7%. Ajovy recorded global sales of $673 million in 2025 (up 30% year-over-year), and Vyepti reached approximately $677 million (up 59%), indicating accelerating category expansion. Vedana's entry point coincides with the inflection point where the transition from a CGRP-only era to a PACAP and dual-pathway era begins, and Lundbeck's Phase 3 entry for bocunebart (expected in the second half of 2026) will further solidify this market shift. Vedana is currently in the preclinical stage and will use the funding to advance its IND-enabling studies.
With the CGRP inhibitor market projected to reach $12.5 billion by 2033, the fact that Dr. Leon Garcia, the original discoverer of the PACAP pathway, has launched a company targeting this pathway reduces the technical risk. Lundbeck's successful Phase 2b trial of bocunebart has already validated the clinical value of the target. The bispecific PACAP+CGRP antibody represents the first dual-pathway strategy targeting patients who do not respond to existing CGRP monotherapies (approximately 30-40% of patients), and positive clinical data could trigger a re-evaluation of the company's valuation. The subcutaneous, long-acting design offers a commercial differentiation compared to IV-administered bocunebart, and the convenience of self-administration could provide a competitive advantage in payer negotiations. The $46 million Series A funding is a significant round for a preclinical-stage migraine biotech company, indicating that specialized VCs such as Westlake and Canaan are making a significant bet on the commercialization of the PACAP pathway. From a neuroscience research and career perspective, PACAP biology and bispecific antibody engineering are areas where demand for talent is expected to surge in the next five years.
Source: FierceBiotech (rss)